leisure time -WSS

leisure time

author：comprehensive 2025-09-28 12:10:14 - browse：23411

A black and white cutout photo of Feng Zhang on the left of a black and white cutout photo of Alex Aravanis. Both photos are placed on top of yellow geometric shapes and a gradient dark blue background. — Researcher Feng Zhang, left, and Alex Aravanis, the CEO of Moonwalk. Illustration: Christine Kao/STAT; Photo: Katherine Taylor for STAT and Business Wire

A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA strand.

Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures. It plans to use that money to develop treatments for a variety of diseases, including chronic and aging-related conditions, using what’s called epigenetic editing.

Most of the gene editing technologies being used today slice or nick the DNA strand and make permanent changes to the biological building blocks of genes. Moonwalk, however, plans to alter the activity of genes by focusing on chemical changes. The company is targeting the surrounding chemicals that influence how genes act. This can be done through chemical processes methylation, which turns genes on, or demethylation, which turns genes off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Private equity deals in Medicare Advantage declines

hotspot

WSS

Key House Republican on health care plans exit from Congress

ProMED sees offers of support, but its future remains unclear

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Beware the threat of staffing cuts at the CDC

ProMED sees offers of support, but its future remains unclear

PhRMA lawsuit over Medicare drug price negotiation tossed

focus

leisure time

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why did Pfizer dish out millions for a Super Bowl ad?

How to save PrEP access — and even expand it

PhRMA lawsuit over Medicare drug price negotiation tossed

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Key House Republican on health care plans exit from Congress

Peter Hotez and the public health issue of online harassment

The dental labor crisis is a moment of opportunity

Jerome Adams on the need for new antivirals for Covid

Trump cancels press conference intended to dispute Georgia election interference charges

hotspot

The Readout: Gilead, Bernie Sanders, and other pharma news

How digital tools helped lower hypertension in marginalized patients

Living with Hashimoto's and celiac disease, and med school, too

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

ProMED sees offers of support, but its future remains unclear

ProMED sees offers of support, but its future remains unclear

hotspot

entertainment

hotspot

hotspot